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Background: There is a growing global interest in formulating such policies and
strategic plans that help devise collaborative working models for community
10pharmacists (CPs) and general practitioners (GPs) in primary care settings.
Objective: To conceptualize a stakeholder-driven framework to improve collaboration
between CPs and GPs in Malaysian primary care to effectively manage medicines in
chronic diseases.
Design and Setting: A qualitative study that involved individual semi-structured inter-
15views of the leadership of various associations, guilds, and societies representing CPs, GPs,
and Nurses in Malaysia.
Methods: This study collected and reported data in accordance with the guidelines of the
Consolidated Criteria for Reporting of Qualitative Studies. Key informants were recruited
based on purposive (expert) sampling. Interviews were transcribed verbatim and data were
20coded based on the principles of thematic analysis in NVivo.
Results: A total of 12 interviews (5 CPs, 5 GPs, and 2 nurses) were conducted. Five themes
emerged: Theme 1 highlighted a comparison of community pharmacy practice in Malaysia
and developed countries; Theme 2 involved current practices in Malaysian primary care;
Theme 3 encompassed the advantages of CP–GP collaboration in chronic diseases; Theme 4
25highlighted the barriers which impede collaboration in Malaysian primary care; and Theme 5
delineated the way forward for CP–GP collaboration in Malaysia.
Conclusion: The actionable insights obtained from the Malaysian stakeholders offered
an outline of a framework to enhance collaboration between CPs and GPs in primary
care. Generally, stakeholders were interested in CP–GP collaboration in primary care and
30identified many positive roles performed by CPs, including prescription review, adher-
ence support, and patient education. The framework of the way forward includes:
separation of CP and GP roles through a holistic revision of relevant legislation to
grant an active role to CPs in chronic care; definition of protocols for collaborative
practices; incentivization of both stakeholders (CPs and GPs); and design and implemen-
35tation of an effective regulatory mechanism whereby the Malaysian Ministry of Health
may take a leading role.
Keywords: community pharmacist, general practitioner, chronic disease, collaborative care,
Malaysia, qualitative research medicine management
Correspondence: Naeem Mubarak
Lahore Medical & Dental College,
University of Health Sciences, Tulspura,





Universiti Islam Antarabangsa, Malaysia
Kampus Kuantan, Pahang Darul Makmur,
Jalan Sultan Ahmad Shah, Bandar Indera




Risk Management and Healthcare Policy 2021:14 1–13 1
© 2021 Mubarak et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the
work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Risk Management and Healthcare Policy Dovepress
open access to scientific and medical research
Open Access Full Text Article
Plain Language Summary
How does this fit in?
What was previously known?
40 ● Effective chronic disease management requires optimal
medicine management. In turn, this needs interprofessional
collaboration. Here, such collaboration is widely thought of
as a desirable model of practice in primary care. Here, the
goal remains delivering a more diverse skill mix to meet
45 the complex demands of chronic patients.
● Even so, there continues to be a general absence of stake-
holder-driven frameworks that can conceptualize a way
forward to enhanced collaboration among GPs and CPs in
primary care in developing countries.
50 What does this study add?
● To our knowledge, this one-of-a-kind study recruited
a geographically diverse panel of healthcare stakeholders
comprised of the leadership of several associations, guilds,
societies, and alliances that represent general practitioners,
55 community pharmacists, and nurses across Malaysia.
● This study fills an important gap in the knowledge and
offers actionable steps to enhance interprofessional colla-
boration between CPs and GPs in private primary care in
Malaysia. Importantly, the study develops these action
60 steps from insights gained through semi-structured inter-
views with relevant Malaysian healthcare stakeholders.
Background
The burden of chronic diseases has now grown to be
a daunting challenge for the Malaysian healthcare system.
65 In fact, Malaysia has a higher prevalence of chronic
diseases than most of its neighbours, except Singapore.1
Optimal chronic disease management requires interprofes-
sional collaboration and utilization of the expertise of
different healthcare professionals. This is also demon-
70 strated in the growing global interest in policies and stra-
tegic plans that seek to enhance interprofessional
collaboration and to deliver a more diverse skill mix to
chronic patients in primary care.2–4
The Malaysian healthcare system is two-tiered. It
75 comprises of a heavily subsidized public sector and
a non-subsidized, rapidly-expanding, private sector. In
Malaysia, primary care — both in the private and the
public sector — bears the burden of chronic diseases.5
Here, these tiers are working according to entirely
80 different models. In the public sector, primary care is
provided through community clinics, such as “Klinik
Kesihatan” (that serves as the first point of care),
“Polyclinics” (an upgraded and extended version of
Klinik Kesihatan), “Klinik Desa” (that provides antena-
85tal and postnatal care), and “1 Malaysia Clinic” (now
rebranded as community clinics and cover the rela-
tively remote areas). In Malaysia, a medical graduate
who owns a private clinic after completion of four
years’ service in public hospitals is commonly referred
90to as a general practitioner (GP).6,7 In the public sector,
there is a satisfactory level of collaboration between
different healthcare professionals. In addition, the prac-
tice of “dispensing separation” exists within the public
sector.8,9 Here, dispensing separation (DS) refers to
95a practice where prescribers such as GPs prescribe
medicines (generics) as per specified formulary and
pharmacists dispense medicines and perform
counselling.
Conversely, in the private sector, primary care is com-
100prised of GPs’ clinics, nursing homes, mental health
clinics, and community pharmacies. Unlike in the public
sector, DS does not exist within the private sector.10
Hence, GPs prescribe as well as dispense medications.
On the other hand, the community pharmacists (CPs)
105represent a subgroup of pharmacists in the private sector
who are mainly involved in selling over-the-counter drugs
or cosmetics at retail outlets commonly referred as phar-
macies. As the law permits a GP to dispense medications
through a clinic, the number of prescriptions received by
110CPs are limited.11 As a result, patients remain deprived of
input from a skilled professional (that is, CP) who could
contribute positively to prescription review or adherence
improvement amongst chronic patients based on their
knowledge, skills, and training. Collaboration between
115GPs and CPs is rare in the private sector; rather, the
situation has turned into a conflict or business rivalry.
Here, it is important to note that, since more than 41%
of Malaysians seek treatment in the private sector, addres-
sing such issues and resolving potential conflicts remains
120a pressing concern.12,13
Despite the existence of many successful collabora-
tive healthcare models in developed countries, colla-
boration is still not a common practice in primary care
in many upper-middle-income countries, including
125Malaysia.12,13 The preceding two decades have wit-
nessed an inadequate response of the Malaysian primary
care system (especially in the private sector) to the
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delivery of well-coordinated interventions to improve
management of medicines in chronic diseases largely
130 due to poor interprofessional collaboration.5,10
Nevertheless, every country has a different culture and
health-seeking behaviours and socio-political dynamics.
Fostering a culture of interprofessional collaboration has
remained a complex challenge. A key issue, here, has
135 been reconciling the different training backgrounds of
relevant stakeholders and positional stakes in the given
healthcare system. Recently, a Delphi survey aimed to
build consensus among healthcare stakeholders in
Malaysia and laid emphasis on CP–GP collaboration
140 for chronic disease management.14 However, lack of
a qualitative research aspect as well as the inherent
limitations of the Likert scale-based survey design
used in the study impeded true exploration of the com-
ments of concerned stakeholders. These comments
145 (Table S1) generated further questions on the issue at
hand and need further clarification of the stakeholders.
In this scenario, a qualitative enquiry utilizing an inter-
pretivist approach could yield a clear framework that
interlinks different constructs to depict a holistic view
150 of the way forward to improve interprofessional colla-
boration in primary care.
Against the above extrapolated background, the key
objective of this study was to propose a conceptual frame-
work — based on the insights of Malaysian healthcare
155 stakeholders — to delineate the way forward to enhance
interprofessional collaboration between GPs and
CPs under a collaborative medication therapy management
model (CMTM) in Malaysia.
Methods
160 The present study was conducted and reported in compli-
ance with the Consolidated Criteria for Reporting
Qualitative Research (COREQ) guidelinesAQ1 (Table S2).15
Selection and Recruitment of Experts/
Key Informants
165 Purposive (expert) sampling was used to recruit key
informants (KIs), that is, the stakeholders interviewed in
this study. As all KIs were recruited from the sample used
in the Delphi study,14 the selection criteria remained the
same as previously reported (Figure S1), with a few addi-
170 tional inclusion criteria. The researchers determined that
the KI must:
1. Have a Master’s degree or, preferably, a PhD (in the
case of academia), or a specialization (in the case of
GPs).
1752. Be available to give consent for a minimum one-
hour interview during specified dates.
3. Have a minimum of five years' experience working
with a GP/CP in the relevant field.
GPs with a specialization (a higher qualification after an
180MBBS degree, such as Family Medicine Specialist in
Malaysia) were preferred. This is because they are more
experienced as frontline healthcare workers who are
involved in chronic disease management in primary care.
Thus, they are the most likely to have first-hand knowl-
185edge of the issues that concern this study.
In Malaysia, the BS Pharmacy degree entitles a candidate
to run a community pharmacy. However, CPs do improve
their qualifications, such as a Master's in Clinical Pharmacy
Practice or a Master's in Community Pharmacy Practice, and
190hence enhance their knowledge and skills. Thus, we pre-
ferred any CP with a Master's degree.
Although the aim was to conceptualize a framework for
improved collaboration between the two healthcare stake-
holders (CPs and GPs), nurses’ representatives were also
195taken on board. This was planned with a view to seek
additional insights because nurses are involved in direct
patient care in the GPs’ clinics. Furthermore, the researchers
view nurses as neutral observers of the purported conflict
between CPs and GPs, and as an important stakeholder in
200any given healthcare system around the globe. Hence, nurses
were added in the sample to further enrich the data.
The sample size for this study was determined by
thematic saturation of the data. An honorarium worth
100 Malaysian Ringgit was granted to each stakeholder
205at the end of the interview.
Semi-Structured Personal Interviews
Semi-structured personal interviews were used as a tool
for data collection. The format of the interview included
open-ended questions to allow KIs to offer additional
210perspectives and thus enable exploration of various aspects
of the way-forward to a CMTM model in Malaysian
primary care setting.
Setting
All face-to-face interviews were conducted in the respec-
215tive KIs' offices and were uninterrupted. The offices were
located in different cities in Malaysia.
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Interview Guide
An interview guide was prepared based on the comments
of the healthcare stakeholders (Table S1) in the Delphi
220 study cited earlier. The interview guide was further refined
following a literature review16–21 and was pilot tested for
any modifications or improvements with one CP, one
nurse, and two GPs, who were not involved in this study
later. Based on their feedback a few open-ended questions
225 were further added to cover the topic under study. The
complete interview guide (Table 1) was sent to all KIs
before the scheduled date of the interviews.
Interview Process
Before the interviews, the KIs were detailed via email and
230 phone call about the research objectives and reasons for inter-
view taking. The first author, a male PhD candidate, was
trained in interview conduct and rapport-building techniques
through short courses. Thefirst author conducted all interviews
according to pre-booked appointments between June 3 and
235 July 15, 2019 in the KIs’ respective offices. As appointments
were pre-booked, the interviews were conducted in comforta-
ble settings and were uninterrupted. The KIs knew the inter-
viewer because of their previous interactions with him during
the Delphi study. A digital interview recorder was used to
240 record the interviews and detailed written notes were taken
by the researcher. As all KIs could understand and speak
English fluently, interviews were conducted in the English
language. Prior to beginning of interviews, the KIs were
assured that they could retract or change any statement in the
245 interview if they wished to do so. At the end of an interview,
audio files were transferred to a secure, password-protected
computer in possession of the research supervisor.
Data Management and Analysis
Data were managed and analyzed using NVivo plus (ver-
250 sion 12, QSR International).
Transcription, Coding, and Theme
Generation
Audio files of interviews were transcribed verbatim
(in Microsoft Word) using Windows Media Player.
255 Transcription was carried out by the first author and counter-
checked by the other two authors (ASK and SK) for any
errors in transcription. The supervisor (CSZ), a native, was
consulted to clarify any confusion due to different dialects/
accents to avoid any misinterpretation. Transcribed Microsoft
260Word documents and field notes were imported into NVivo for
descriptive and interpretivist analysis.
Transcripts were coded by two authors (NM and SK)
independently, based on the principles of thematic analysis
and the constant comparison approach.22 Nodes depict the
265way in which data were carried through analysis from spe-
cific to broader codes (themes).23 Coding of the transcripts
involved carefully reading and re-reading of all the transcript
(data) word by word, linking and connecting texts, and high-
lighting various texts with different colours as per their suit-
270ability for a distinct construct or context. Any conflict in
coding was resolved by involving the supervisor (CSZ) in
the process to reach a consensus. Field notes helped in recal-
ling the interview event and thus facilitated data analysis.
Trustworthiness, Credibility, and
275Respondent Validity
Trustworthiness or rigour in qualitative research involves
credibility, transferability, confirmability, and dependability.
To enhance credibility, data were collected and reported as
per COREQ guidelines. Furthermore, the audio and written
280verbatim versions of the interviews and all transcripts were
counter-checked. Coding and resulting theme generation
were verified by the supervisor and two other researchers
from the supervisory team. All investigators removed any
disagreement on emergent themes through consensus.
285Furthermore, negative case analysis was utilized to substanti-
ate the themes. To ensure transferability of this qualitative
study, researchers provided thick descriptions of the
phenomena and settings, including the relevant sociocultural
background of the stakeholders (age, gender, education,
290affiliations; see Tables 2 and 3). “Respondent’s validity”
was used as a technique to ensure confirmability, that is, all
transcribed files were sent via email to the interviewee to
correct and send back if anything was not recorded or tran-
scribed accurately. However, none reported any significant
295error in transcriptions. Finally, dependability was established
through a well-maintained audit trail of all process logs.
These logs are available from the corresponding author for
auditing purposes.
Theoretical Saturation
300Data saturation was viewed as achieved when no new
themes were evident. Interviews were based on the plus-one
principle, which states that when researchers assume that no
new themes are emerging, the process of interviews may be
stopped after one more interview.23
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305 Ethics
Informed consent was obtained from all KIs after provid-
ing them with information (Supplementary file S1) on the
research aims and objectives. To ensure anonymity, KIs
were assigned individual identification numbers. The con-
310 sent included publication of anonymized responses.
Results
The first author conducted a total of 12 interviews (five CPs,
five GPs, and two nurses) for a total duration of 636 mins.
The average time of an interview was 50.29 min (longest and
315 shortest interviews were of 77.4 mins and 34.18 mins dura-
tion, respectively). The response rate was 92% (13 KIs were
contacted and 1 refused due to a schedule conflict). All
interviews were conducted face to face, with the exception
of one that was taken via the phone (personal preference of
320 KI). After the ninth interview, saturation of data occurred.
However, three additional interviews were conducted to con-
firm data saturation
Themes
The KIs offered actionable insights on different aspects of the
325CMTMmodel which facilitated the formation of a conceptual
framework outlining the way forward to a CMTMmodel. Five
main themes emerged from the collected data. Details of the
sub-themes, field notes, and insights are provided in Tables
S3–S7 for themes 1, 2, 3, 4, and 5, respectively.
330Demographics of the Key Informants
Demographic data (Table 1 and Figure 1) and the diverse
affiliations of KIs with various professional organizations
representing GPs, CPs, and nurses in Malaysia are given in
Table 2. GPs and CPs are represented equally, that is, five
335of each. The median age of the KIs was 50 (range =
Table 1 Interview Guide
Interview Questions
Part 1 1. Do you see any differences between the practice of community pharmacy in developed countries and in Malaysia? If yes, what are the main
differences?
2. What are your views on collaboration of a CP with private GP clinics to provide a collaborative medication therapy management service for
chronic disease patients where the CP takes a more active role in patient care?
3. Do you think education and counselling on medicine and disease provided by GPs is sufficient for the patients, and additional educational or
counselling activities would have no additional benefits?
4. What would be the first practical step towards such collaboration if we move towards this goal?
5. Is there any prescription review service in Malaysia? Do you think prescription review by a CP specifically trained for a chronic disease would be
advantageous? If yes, what might be the advantages.
Part 2 1. Do you think such collaborative practice can improve patients’ clinical outcomes? If yes, how?
2. Do you think such collaborative practice can improve patients’ outcomes, adherence, compliance, and quality of life? If yes, how?
3. Do you think the service represents value for money for the government? Does it have some economic benefit?
4. How could the formation of a national electronic prescription record system for chronic diseases make such activity more result-oriented/
fruitful?
Part 3 1. What is the most important barrier you consider relevant in the Malaysian setting and what are possible solutions?
2. How can we minimize role encroachment or overlap?
3. Do you think, on legal or regulatory grounds, it would be a challenging task to formulate such protocols?
4. How could political will be influenced in favour of a CMTM service?
5. Do you think CPs in Malaysia have the necessary knowledge and expertise/training to undertake this expanding role in medicine management
for chronic diseases? If not, in which area are they lacking?
6. Do you think GPs’ concern regarding the clinical incompetence of CPs can be minimized by providing appropriate, authentic (approved by the
MoH), and mandatory diplomas/training/courses on specific chronic diseases, their clinical picture, and patients, and by improving commu-
nication between CPs and GPs?
7. Do you think collaboration in the form of a CMTM service is a threat to GP clinic business? If yes, how would you minimize/tackle this issue?
8. Do GPs feel concern about sharing of patients' information and the liability of CPs? If yes, how do you suggest dealing with these concerns from
the perspective of either a GP or a CP?
9. Whatstrategies do you feel may strengthen trust between GPs and CPs?
10. How much do you think dispensing separation is linked with collaboration? Do you feel that, without dispensing separation, collaboration is
impossible or may be attainable? Why/how?
11. How do you think the public could be made aware of the role of the pharmacist?
Do you think CPs should be compensated for such services? Which method of payment (UHC, third-party payer, or direct billing/fee for
service) would be most feasible in the Malaysian setting and why?
Part 4 What role would you like or consider appropriate/inappropriate to be performed by CPs in chronic disease management?
Do you wish to add any additional comments which may be valuable, in your experience, if we move towards this collaborative model in future?
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40–62), while the median number of years of experience
was 24 years (range = 17–39).
Theme 1. Community Pharmacy Practice:
Understanding the Difference Between
340 Malaysia and Developed Countries
This theme highlighted KIs’ recognition of the differences
in practice of community pharmacies in developed coun-
tries and Malaysia. One participant noted:
“In Malaysia our GPs can prescribe, and they can dis-
345 pense, it does not happen in developed countries where
CP offers dispensing, educational and adherence support
to patients.” (GP 3)
Similarly, another participant stated that:
“Of course, there’s a vast difference between the practice
350of pharmacy in developing countries and Malaysia for
example we don’t have our DS and the GPs are dispensing
the medication.” (CP 2)
Theme 2. Current Practices in Primary
Care in Malaysia
355In this theme, the KIs discussed the current situation of
primary care in Malaysia pertaining to law, policy, and
malpractices as they relate to GPs and CPs. One partici-
pant informed the researcher that:
Table 2 Demographics and General Characteristics of Key Informants
Characteristics Category n (%) where, nt= 12
GP (n = 5) CP (n = 5) Nurse (n = 2) Total
Gender Male 3 (25) 5 (41.7) 1 (8.3) 9 (75)
Female 2 (16.7) 0 1 (8.3) 3 (25)
Age group 36–45 0 0 1 (8.3) 1 (8.3)
46–55 3 (25) 2 (16.7) 1 (8.3) 6 (50)
56–65 2 (16.7) 3 (25) 0 5 (41.7)
Does your training curricula include interprofessional
collaborative practice?
Yes 3 (25) 2 (16.7) 1 (8.3) 6 (50)
No 2 (16.7) 3 (25) 1 (8.3) 6 (50)
Total experience (number of years) 15–20 1 (8.3) 1 (8.3) 1 (8.3) 3 (25)
21–25 3 (25) 0 0 3 (25)
26–30 0 1 (8.3) 1 (8.3) 2 (16.6)
31–35 1 (8.3) 0 0 1 (8.3)
36-40 0 3 (25) 0 3 (25)
Where did you get your training (ie, education and experience)
in your related field from?
Local 1 (8.3) 3 (25) 1 (8.3) 5 (41.7)
Both Local and
International
4 (33.3) 2 (16.7) 1 (8.3) 7 (58.3)
Have you ever worked professionally with a CP? Yes 4 (33.3) NA 2 (16.7) 6 (50)
No 1 (8.3) NA 0 1 (8.3)
NA - 5 (41.7) - 5 (41.7)
Have you ever worked professionally with a GP? Yes NA 4 (33.3) 2 (16.7) 6 (50)
No NA 1 (8.3) 0 1 (8.3)
NA 5 (41.7) - - 5 (41.7)
If you are in academia, into which category do you fall? Professor 1 (8.3) 1 (8.3) 0 2 (16.6)
Associate
Professor
2 (16.7) 0 1 (8.3) 3 (25)
Assistant Professor 0 0 0 0
Not in Academia 2 (16.7) 4 (33.3) 1 (8.3) 7 (58.3)
Highest qualification/degree PhD 2 (16.7) 1 (8.3) 1 (8.3) 4 (33.3)
Master 3 (25) 0 1 (8.3) 4 (33.3)
Bachelor 0 4 (33.3) 0 4 (33.3)
Abbreviations: GP, general practitioner; CP, community pharmacist; NA, not applicable.
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“The GPs' side are making money out of the dispensing
360 process, in doing so overprescribing is too high in private
clinics.” (CP 4)
Another KI raised concerns about GP malpractices:
“GPs are trying to use expensive new medicine, for med-
ical condition. So, that the patient will not be able to find it
365 elsewhere because the pharmaceutical supplier only gives
those new medicines to the GP’s clinic. So, they manip-
ulate market through this practice.” (CP 5)
Two KIs highlighted the need for a prescription review
and utilization of the expertise of other healthcare profes-
370 sionals in the private sector:
“In public sector, the prescriptions are reviewed all the
time, because prescription is sent to the pharmacist and
pharmacist will see prescription before dispensing. No
doubt, Patient safety is greatly enhanced by having a CP.
375 It doesn’t matter really, we are in private or public, the
care process should be the same.” (GP 4)
“It’s a chronic disease so, to be just one provider, sometimes
is just not enough. To drive home message, they need to hear
it from many aspects, from many people.” (GP 1)
380Similarly, another observation was:
“CPs in Malaysia are very commercialized, dispense pre-
scription medicines without prescription, gives wrong
advice, promote supplements over medicine/nonevidence
based therapy, doing lab tests etc. Currently there are cases
385of cardiac failure being diagnosed and treated for walk in
patients without consulting a GP/Doctor resulting GPs low
trust in the pharmacists.” (GP 3)
Theme 3. Potential Advantages of CP–GP
Collaboration in Chronic Disease
390Management
The KIs detailed the advantages of CP–GP collaboration
for patients, professionals, and government. A participant
informed the researcher that:
Table 3 Field/Area of Expertise and Professional Associations or Affiliations of Key Informants
Attribute Category n (%) where, N = 12
GP (n = 5) CP (n = 5) Nurse (n = 2)
Field/Area of expertise* General Practitioner 5 (41.7) Pharmacist in Academia 1 (8.3) Nurse in Academia 1 (8.3)
General Practitioner in Academia 3 (25) Pharmacist in Hospital 1 (8.3) Nurse practicing with GP
1 (8.3)
Family Medicine Specialist 5 (41.7) Pharmacist in Community Pharmacy
5 (41.7)
Nurse in Hospital 1 (8.3)
Professional associations
or affiliations*
Ministry of Higher Education 1 (8.3) Ministry of Higher Education 1 (8.3) Ministry of Higher
Education 2 (16.7)
Ministry of Health 2 (16.7) Ministry of Health 1 (8.3) Ministry of Health 0
Family Medicine Specialist Association
Malaysia 5 (41.7)








Federation of Private Medical Practitioners’
Association Malaysia 0
Pharmacy Board/Pharmaceutical
Services Division 2 (16.7)
Malaysian Medical Council 1 (8.3)
Malaysian Medical Association 1 (8.3)
Medical Practitioners Coalition Association
of Malaysia 1 (8.3)
Malaysian Primary Care Network 2 (16.7)
Note: *All KIs could choose more than one option for field/area of expertise and professional associations or affiliations, if applicable.
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“The healthcare system has become more complex in
395 chronic care. I think CP should take their active role. We
are not supporting one another’s role, but we should be
collaborative and promote patient safety as errors in pre-
scription by GP can be picked up by CP.” (GP 4)
Another participant was of the view:
400 “We see this from the business angle, that’s why the trust
is difficult to develop but if you see from the patients angle
you want to give the benefit to patient through this colla-
boration.” (GP 5)
Finally, a third concluded:
405 “Collaboration between GP and CP will help to improve
the compliance of many of the chronic diseases and it
would happen when it’s a teamwork, with multidisciplin-
ary team.” (GP 1)
Theme 4. Major Barriers to CP–GP
410 Collaboration
The KIs identified a range of barriers that impede colla-
boration in the Malaysian context, such as absence of DS,
GPs’ conflict of interest, lack of awareness of CPs role,
and absence of trust between the two stakeholders. This
415 may be evidenced from the following comment by a KI:
“I think the biggest threat to the private GPs will be
reduction of income. GPs do not make much money
from consultation under the current consultation rate.
They make money from dispensing drugs. That is the
420main reason why they do not agree to the ‘separation of
function’.” (GP 1)
Another participant poignantly observed that:
“Sending patients to two different places (CP and GP)
would practically fragment the healthcare system and suf-
425focate patients.” (GP 4)
Expressing concern, a participant noted that:
“There will be role encroachment of GPs, patients once
referred to pharmacies would not be back.” (GP 3)
Theme 5. Way Forward Towards
430Enhanced CP–GP Collaboration in
Malaysia Following a Collaborative
Medication Therapy Management Model
Generally, the KIs viewed offering certain clinical roles in
chronic disease management to CPs positively, such as
435giving advice on the cost-effectiveness of prescriptions,
providing prescription/medicine-use reviews and educa-
tion, and offering adherence support. In this context, an
interviewee said that:
“Definitely, prescription review, advice on cost effective
440prescribing and adherence support are the roles which the
pharmacists can play, and you know about half of the
medication errors lead to prescription errors. But dose
adjustment has to be done collaboratively. The pharmacy
needs to contact GPs and discuss with the GPs in terms of
445dose adjustments.” (GP 4)
The GPs also feel that Malaysia is not yet ready for DS
because of an inadequate number of pharmacies, CPs and
operating hours. They feel that this will discomfort patients,
especially in areas where there are few pharmacies, for
450instance in Shah Alam, Sabah, and Sarawak. Furthermore,
dispensing GPs already charge nominal fees as low as
15MYR. Here, then, DS would result in a hike in GPs’
consultation fees, which would have adverse implications
for the private healthcare sector. KIs, especially CPs,
455declared these views as ignorant of the facts and character-
ized them as old rhetoric which hampered the proposal of
CPs’ role expansion in 1990 when there were not enough
CPs. However, it is no more valid today, they reported.
Participants noted that the growth of pharmacies has made
460community pharmacies conveniently available to the public
Figure 1 Geographical diversity of key informants across Malaysia.
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and Malaysia has already met the WHO required number of
pharmacists as per population needs. Furthermore, CPs
reported not having patients at the moment. If CMTM-type
services were in operation, the number of hours would
465 automatically be extended.
In this context, participants noted the following:
“Separation of function is the way forward. But problems
with remuneration for both GPs and CPs must be
addressed through universal coverage under the national
470 health financing scheme which is long overdue.” (GP 1)
One of the KIs suggested that the most feasible remunera-
tion method for CMTM in the Malaysian setting would be
either third-party payer or universal health coverage:
“At present, I think the universal health coverage, or the third-
475 party payer will be appropriate because the insurance com-
pany can paymoney to fund this type of collaboration.” (CP 4)
Thus, this study suggests that the most feasible remuneration
model for CMTM in theMalaysian setting will be either third-
party payer or universal health coverage. This is based on the
480 following view, that was also reflected in other interviews:
“We can follow the models like, in Australia … or in UK,
what, they also have the non-dispensing pharmacist there,
at least we should try.” (CP 4)
Two KIs opted for a win–win situation. One noted:
485 “To produce a collaborative working environment, we
should aim for a win–win situation for everyone, we do
not want GP or CP to suffer, and we want the patients to
benefit from all this.” (CP 2)
The other stated:
490 “All the communications and all the roles must be defined
clearly, both GP and CP should be compensated … There
is something that is very positive about CMTM model it is
for the benefits of Malays.” (GP1)
Concept mapping of the various propositions of KIs,
495 including the positively viewed role of CPs leads to
a conceptual framework of the way forward towards the
CMTM model in Malaysia, as shown in Figure 2 (the
coding tree has been provided in Figure S2).
Discussion
500 Given the above, it seems logical that different healthcare
professionals should collaborate to offer patients a combined
set of expertise. However, practically, this first needs
a behavioural change in the way these stakeholders perceive
each other. The theory of reasoned action highlights that
505collaboration will be successful only if it is viewed as “use-
ful” by both partners.24 The CMTM model conceived in this
study was perceived as being useful by all stakeholders;
however, complexity arises because of conflicts of interest,
differential positioning, and powers and stakes of different
510professionals within the healthcare system.
Furthermore, role theory covers the definition, clarifi-
cation, and labelling of roles assumed in society. These
labels augment formation of assumptions which may lose
validity with the passage of time. In this context, GPs in
515Malaysia used to perceive the role of CPs as retailers and
that stereotypical image hinders successful collaboration
even today. GPs’ reluctance to collaborate with CPs may
be resolved with clarity in defining the new roles of CPs.
For instance, in the UK, initially GPs were against the idea
520of collaborative practices because of their perception
of CPs as “shopkeepers”. However, after initial phases of
social interaction, they came to value the contributions of
CPs in improving adherence and quality in the medicine-
use process.25 Furthermore, based on the positive experi-
525ence with CPs, a recent panel of healthcare stakeholders in
the UK recommended further expansion of the collabora-
tion between CPs and GPs to promote community phar-
macy services for long-term conditions.26
On the other hand, the decades-old conflict regarding
530dispensing separation in Malaysia is still ongoing, and GPs
are not ready to give away this right to pharmacists. This
could be a possible reason why the Ministry of Health,
Malaysia is still reluctant to support such an initiative.
Further action on this remains stymied because of the
535higher stakes of the GPs in the healthcare system and the
lack of proactive lobbying from the CPs’ side, whereby
they could claim DS as their fundamental right and point
out that it is now an internationally accepted and preferred
practice.25 However, we agree with this view only to the
540extent that future policy regarding DS in Malaysia should
be comprehensive as it may hit the financial interests
of GPs.
Furthermore, remuneration models for collaborative
practices vary from country to country. For instance, the
545Australian model of remuneration entails a win–win situa-
tion and reimburses both GPs (for referrals) and CPs (for
services).27 However, in the Malaysian context, as the
results suggest, choosing a method of remuneration is not
straightforward. In effect, diverse factors influence the
550choice of remuneration method; for instance, budget
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constraints, payers’ perspectives, awareness levels, and
value of the services being provided can be seen as some
of the most pressing issues.
The findings of this study may be broadly correlated with
555 those of a recent qualitative study in Brazil, where a similar
exercise was carried out using relevant healthcare
stakeholders to explore new models of care with an aim to
involve CPs in medicine management of chronic diseases.28
Another study in Canada engaged healthcare stakeholders to
560 identify various enablers of effective integration of commu-
nity pharmacy with primary care. This study offered similar
results to ours regarding various discordant perceptions, con-
cerns, and conflicts of interest.29 However, we noted one
formidable difference: nearly all developed countries have
565 a perfect DS system in practice whereas, in Malaysia, this
issue has emerged as a major barrier to collaboration. An
important point to establish here is that the barriers to and
facilitators of collaboration identified in this study are some-
how similar to those enlisted in a recent systematic review
570 that summarized factors affecting collaboration between
CPs and GPs around the globe.30
Results of this study not only confirmed the findings of
the previous Delphi study14 but also explored the way
forward for a number of barriers erected previously. For
575instance, the current study implied that CPs’ role expan-
sion in the proposed CMTM model might not be
a comfortable change for all. A few GPs also recorded
pertinent concerns, for instance regarding CPs' lack of
clinical competencies. However, these concerns, if
580addressed, could result in building trust. The KIs in this
study suggested that special training (an accredited speci-
ality course or a diploma in specific chronic disease man-
agement) and extra accreditation requirements for CPs
may resolve this issue. Literature also supports
585the finding that CMTM type of collaborative services
require greater clinical knowledge and skills for specific
chronic diseases.31 Professional organizations representing
pharmacists, such as the Malaysian Pharmaceutical
Society and the Community Pharmacy Guild Malaysia,
590can play a leading role in training CPs for a more clinical
role in chronic disease management. Similarly, this frame-
work offers key solutions to various problems in the minds
Figure 2 Concept mapping of the way forward towards a collaborative medication therapy management model in Malaysia.
Abbreviations: CP, community pharmacist; GP, general practitioner; PR/MUR, prescription review/medicine-use review; CPA, collaborative practice agreement; UHC,
universal health coverage; MoH, Ministry of Health.
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of GPs; in particular, it addresses key monetary concerns
of GPs by proposing a possible win–win situation in the
595 form of third-party payer or universal health coverage.
Regarding policy, the concerned authorities in
Malaysia should take advantage of the framework of the
way forward to a CMTM model and consider changing the
way policy governs the scope of practice in community
600 pharmacy. For instance, the framework may be used as an
outline upon which to build and further develop a more
robust framework as more input is received from addi-
tional stakeholders in the process.
TheKIs also emphasized that futuremedical and pharmacy
605 education should focus on and practise interprofessional col-
laboration right from the beginning to eradicate the silo-mind-
set that is at the root of this issue. This proposition is also in-line
with the findings of a recent study that used combined phar-
macotherapy workshops for medical and pharmacy students.
610 Post-intervention results indicated significant positive
improvements in attitude towards interprofessional
collaboration.32
A self-sustained collaborative model needs external
forces, internal motivations, and a win–win situation for
615 all members in a team. In this context, political will can
act as an external force which can ensure sustained colla-
boration in primary care. The results of this study suggest
that to influence political will, firstly, political leadership
and bureaucracy need to understand the economic benefits
620 of such collaboration through an evidence-based finding;
furthermore, the GPs in Malaysia should acknowledge the
benefits of having a CP in the chronic care team. Secondly,
public awareness of the advantages of the CMTM model
needs to be improved. This conceptual framework may be
625 advocated and advertised for this purpose in print and
social media.
Finally, a more extensive pilot study merits considera-
tion as a natural extension of this exploratory study to
evaluate the ground dynamics of collaborative practice.
630 For instance, in a big city, a chain of pharmacies may be
connected with GPs to document the benefits and risks.
Strengths and Limitations
The study had the following strengths:
The study, one of its kind in theMalaysian setting, recruited
635 a geographically diverse panel of healthcare stakeholders com-
prising of the leadership of various associations, guilds, socie-
ties, and alliances in the medical, nursing and pharmacy
professions, academia and Ministry of Health, Malaysia, to
offer a framework for enhanced interprofessional collaboration
640between GPs and CPs in primary care. The way forward to the
successful CMTM model conceived in this study fills an
important gap in the literature and presents possibilities and
advantages of an avenue of collaboration between the GP and
CP in primary care in Malaysia operating through community
645pharmacies. The study highlighted GPs' concerns and also
discussed trust-building measures between CPs and GPs. The
findings may be applicable to other countries in the Asia
Pacific region in a similar situation regarding interprofessional
collaboration in primary care.
650The limitations of the study include:
Because transcribing the interviews was excessively time-
consuming, it was not practically possible to precisely infer
where the data saturation point occurred. However, three addi-
tional interviews compensated for this limitation. English was
655not the first language of either the interviewer or the intervie-
wees. Although the KIs were well-qualified they had different
English accents to the interviewer. This aspect might have
produced some bias in transcribing. However, the supervisor
was Malay, thus it was partially compensated for when the
660transcribingwas counter-checked. TheKIswere taken from an
already formed panel and no new expert was added. Though it
is logical to have experts who knew the background of this
study and had participated in the Delphi phase, the addition of
new members (outside of the Delphi panel) could further
665enrich data. Neither patients nor members of the public were
taken on board to explore the issue from their perspectives.
However, not involving these people was deliberate because
many studies have been published describing the favourable
views of the public/patients regarding extending the role
670of CPs.
Conclusion
This study engaged Malaysian healthcare stakeholders to
offer a framework of the way forward for enhancing colla-
boration between CPs and GPs in primary care settings for
675chronic diseases. Generally, the KIs were interested in such
collaboration and viewed the many roles of CPs in chronic
patient care positively. The framework of the way forward
should, then, include: defined protocols for collaborative
practices; incentives for both CPs and GPs; revision of
680relevant legislation to grant CPs an active role in chronic
care; and, regulatory checks under the leadership of the
Ministry of Health. The authors of this study suggest that
Malaysian primary healthcare must also encompass new
models of care based on a collaborative working philosophy
685to utilize its strength (the CPs) today to deliver high-quality
patient care tomorrow.
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